Author: admin

  • Life’s building blocks found in a baby star’s planet-forming disc

    Life’s building blocks found in a baby star’s planet-forming disc

    A baby star is lighting up more than just its corner of space – it’s also revealing the raw ingredients that could eventually form life.

    Astronomers have detected 17 complex organic molecules in the planet-forming disc around a young star called V883 Orionis. Among them are ethylene glycol and glycolonitrile – two molecules long suspected but never before seen in this kind of environment.


    These findings come from a team at the Max Planck Institute for Astronomy (MPIA), using the Atacama Large Millimeter/submillimeter Array (ALMA) in Chile.

    The study offers new insight into how life’s chemistry might emerge well before planets fully form.

    Star stirs up organic soup

    V883 Orionis isn’t an ordinary young star. It’s in the middle of a growth spurt, pulling in gas and blasting out intense energy.

    The outburst temporarily heats its surrounding disc of dust and ice, releasing complex molecules that frozen grains usually trap. These molecules become visible to astronomers using tools like ALMA, which can detect the radio signals they emit.

    “Complex molecules, including ethylene glycol and glycolonitrile, radiate at radio frequencies,” said MPIA scientist Kamber Schwarz. “ALMA is perfectly suited to detect those signals.”

    The detected molecules include precursors to amino acids like glycine and alanine, and even adenine, one of the building blocks of DNA. Ethylene glycol – the same compound used in antifreeze – also plays a role in prebiotic chemistry.

    “We recently found ethylene glycol could form by UV irradiation of ethanolamine, a molecule that was recently discovered in space,” said Tushar Suhasaria, co-author and head of MPIA’s Origins of Life Lab.

    “This finding supports the idea that ethylene glycol could form in those environments, but also in later stages of molecular evolution, where UV irradiation is dominant.”

    Origins of life-friendly chemistry

    Scientists have long wondered when and where life-friendly chemistry begins – and whether it starts before a star fully forms.

    For a while, the assumption was that dramatic transitions – like the shift from a protostar to a fully formed star – would wipe out fragile organic molecules.

    That led to a theory called the “reset” model, where any life-forming compounds would have to rebuild from scratch in newly forming planetary discs. But new evidence from V883 Orionis challenges that idea.

    “Our finding points to a straight line of chemical enrichment and increasing complexity between interstellar clouds and fully evolved planetary systems,” said Abubakar Fadul of MPIA.

    Star formation doesn’t erase life

    Instead of being erased, complex molecules may survive early star formation and carry over into planet-forming regions.

    “Now it appears the opposite is true,” explained Schwarz. “Our results suggest that protoplanetary discs inherit complex molecules from earlier stages, and the formation of complex molecules can continue during the protoplanetary disc stage.”

    That would mean the seeds of biology – like amino acids, sugars, and nucleobases – are not just possible in one solar system but likely common across the universe.

    How stars trigger molecule release

    The chemistry behind these molecules starts small and cold. Dust grains in space act like tiny laboratories, where atoms and simple molecules stick to icy surfaces and gradually become more complex. These ice-bound compounds are nearly impossible to detect – unless something heats them up.

    That’s where young stars like V883 Orionis come in. When the star pulls in more gas, it emits powerful radiation that warms even the outer parts of its disc.

    “These outbursts are strong enough to heat the surrounding disc as far as otherwise icy environments, releasing the chemicals we have detected,” said Fadul.

    The heating process is similar to what happens with comets in our own Solar System. As they approach the Sun, their icy surfaces vaporize, forming visible tails and releasing trapped organic molecules.

    The search for life’s chemistry isn’t over

    The MPIA team knows there’s more to uncover. Though this discovery is major, their spectral data still holds mysteries.

    “While this result is exciting, we still haven’t disentangled all the signatures we found in our spectra,” said Schwarz. “Higher resolution data will confirm the detections of ethylene glycol and glycolonitrile – and maybe even reveal more complex chemicals we simply haven’t identified yet.”

    “Perhaps we also need to look at other regions of the electromagnetic spectrum to find even more evolved molecules,” noted Fadul. “Who knows what else we might discover?”

    Universe favors life’s chemistry

    Finding these complex organic molecules in a young star’s disc reinforces a bigger idea: the universe might have wired itself chemically for life from the start.

    If molecules like these are common in planet-forming regions, then life-friendly chemistry could be happening everywhere – and not just by chance.

    This doesn’t mean we’ve found life, or even direct evidence of it. But it does mean the starting materials are out there, hiding in the ice, waiting for a star to wake them up.

    The full study was published in the journal The Astrophysical Journal Letters.

    —–

    Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates. 

    Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

    —–

    Continue Reading

  • New circuit, no problem for these MotoGP stars

    New circuit, no problem for these MotoGP stars

    It’s going to be a historic Round 14 for the World Championship in 2025, as Balaton Park becomes the latest venue to embrace the pinnacle of motorcycle racing, with anticipation mounting for the Grand Prix of Hungary. A fresh challenge awaits the MotoGP elite, but which riders have come out on top when we’ve first visited new tracks?

    Within the current grid, there are a number of riders who could be considered new track masters, not least Miguel Oliveira (Prima Pramac Yamaha MotoGP) At the 2022 Indonesian GP, the Portuguese rider had the honour of being the first rider to ever win a MotoGP race at Mandalika. Oliveira has made a habit of achieving such feats, having also come out victorious when MotoGP first visited Portimao’s Algarve International Circuit in 2020, so expect him to be a rider to adapt quickly too.

    That record places him joint-second on the list of wins at new circuits during the MotoGP era, with six-time MotoGP Champion Marc Marquez topping the list with three. The Ducati Lenovo Team rider counts opening wins at the USA’s Circuit of The Americas in 2013, Argentina’s Termas de Rio Hondo in 2014 and Thailand’s Buriram International Circuit in 2018 amongst his list of many sporting accolades.

    Since 2002, seven other circuits have made their debuts on the MotoGP calendar. The latest being India’s Buddh International Circuit, where Marco Bezzecchi (Aprilia Racing) triumphed.

    Elsewhere, the Qatar GP was first won by Sete Gibernau on Honda’s RC211V. In 2005, China’s Shanghai International Circuit saw its maiden race go the way of Valentino Rossi, while later that season, Marco Melandri took the win at the first-ever Turkish GP at Istanbul Park.

    Three years later, Rossi pocketed victory at the Indianapolis Motor Speedway before we saw MotorLand Aragon make its debut in 2010, with Casey Stoner standing on the top step of the podium for the final time with Ducati. 2016 saw the Red Bull Ring in Austria arrive on the calendar, with Andrea Iannone claiming victory there.

    In terms of tracks that came back after a lengthy absence, Silverstone springs to mind, and the world-famous circuit was back in 2010 with Jorge Lorenzo emerging victorious. Before that, Misano in 2007 was a home round to remember for Ducati as Casey Stoner took honours after the track’s 14-year hiatus and also Laguna Seca in 2005 after 11 years away, welcoming Nicky Hayden’s first win. 

    Will a new name be added to the list at Balaton Park? 

    Continue Reading

  • Tech and financial services power stronger US output growth in July – S&P Global

    1. Tech and financial services power stronger US output growth in July  S&P Global
    2. Services PMI® at 50.1%; July 2025 Services ISM® Report On Business®  PR Newswire
    3. Bitcoin Price (BTC) News: Lower on Tuesday  CoinDesk
    4. US services sector stalls in July amid rising tariffs and weakening job market: reports  Global Times
    5. Why Did Stocks Pick Weak vs. Strong US PMI Data to Trade On?  tastylive

    Continue Reading

  • How to get the Power Rangers skins in Fortnite today? | Esports News

    How to get the Power Rangers skins in Fortnite today? | Esports News

    Fortnite has recently announced its highly awaited collaboration with the Power Rangers. In this crossover, we will see The Mighty Morphin Power Rangers take action against the Kraken-borne bugs in Chapter 6 Season 4 in Fortnite.From the Mighty Morphin Megazord to themed weapons like the Swarmstrike Launcher and the OG “Go Go Power Rangers” theme song, this collaboration will have everything it it. However, the highlight of this collab has to be the Power Rangers costume, which fans can get early even before its actual release.

    Players can get the Red and Pink Ranger outfits early in Fortnite

    fortnite-power-ranger-cup

    Red and Pink Power Ranger Cups will gran players Power Ranger skins. | Image via Epic Games.

    Just like players were able to notch up the Fantastic Four skins early before their release by participating in the Fantastic Four Cup in Fortnite, now there is another couple of tournaments which can grant two Power Ranger skins early – Red Ranger Cup and Pink Ranger Cup.Both the cups are going to take place on August 6, 2025. These are going to solo tournaments, where players will take part in standard Battle Royale matches. Players need to check out the in-game Compete tab to know the exact timings of these tournaments as they will vary depending upon different locations and timezones. The Red and Pink Rangers Cup will be available for only three hours. In this short span, players can enter a maximum of 10 matches per cup. If you are thinking about maximizing your chances by taking part in both the cups, then keep in mind that they will become live simultaneously and will expire at the same time.As the name suggests, these two cups will grant the Red Ranger and Pink Ranger outfits respectively. But how to get them? In order to obtain these skins for absolutely free, players need to be on the top spots for different regions in these tournaments. Players can score points to be in the leaderboards by winning matches and eliminating opponent players. Here is the region wise breakdown and top spots to secure the skins:

    Region
    Brazil Top 200 players
    Europe Top 2,000 players
    Ocenia Top 200 players
    NA-West Top 200 players
    NA-Central Top 1,800 players
    Middle East Top 200 players
    Asia Top 200 players

    Another interesting fact about these cups are that, these aren’t region locked. So, if you are facing difficulties to be in the leaderboard in your native regions, then you will always have the option to change your server to any location for a favorable condition.However, those who fail to be in the top spots in these two cups, don’t need to be disappointed at all. If any player manages to score 8 points in either of the tournaments, then he will be rewarded with the Jason’s Mark Spray (Red Ranger Cup) or the Kimberly Was Here Spray (Pink Ranger Cup) or both.Usually players get their rewards from such tournaments immediately after these end. But the Red Ranger and Pink Ranger outfits will be available to the tournament winners at the start of Chapter 6 Season 4. Read More: Every Fortnite X Power Ranger collab details explained


    Continue Reading

  • White Shark DNA Split Puzzles Scientists

    White Shark DNA Split Puzzles Scientists

    White sharks (Carcharodon carcharias) almost went bottom-up during the last ice age, when sea levels were much lower than they are today and sharks had to get by with less space. The most recent cold snap ended about 10,000 years ago, and the planet has been gradually warming ever since. As temperatures increased, glaciers melted, and sea levels rose, which was good news for great whites.

    Results of a study published in the journal Proceedings of the National Academy of Sciences show that white sharks had been reduced to a single, well-mixed population somewhere in the southern Indo-Pacific Ocean. White sharks began genetically diverging about 7,000 years ago, suggesting that they had broken up into two or more isolated populations by this time.

    This is new information but not particularly surprising. There are never many white sharks around even at the best of times, as befits their status at the top of the tapered food chain, where a lack of elbow room limits their numbers. Today, there are three genetically distinct white shark populations: one in the southern hemisphere around Australia and South Africa, one in the northern Atlantic and another in the northern Pacific. Though widespread, the number of white sharks still remains low.

    “There are probably about 20,000 individuals globally,” said study co-author Gavin Naylor, director of the Florida Program for Shark Research at the Florida Museum of Natural History. “There are more fruit flies in any given city than there are great white sharks in the entire world.”

    Organisms with small populations can be pushed dangerously close to the edge of extinction when times are tough. Mile-high glaciers extended from the poles and locked away so much water that by 25,000 years ago, sea levels had plunged by about 40 meters (131 feet), eliminating habitat and restricting great whites to an oceanic corral.

    But something happened to great whites during their big comeback that remains as much of a mystery now as it was when it was first discovered more than 20 years ago. The primary motivation for this study was to lay out a definitive explanation, but despite using one of the largest genetic datasets on white sharks ever compiled, things did not go quite according to plan.

    “The honest scientific answer is we have no idea,” Naylor said.

    Female great white sharks wander off for years to feed but come back home to breed

    Scientists first got a whiff of something strange in 2001, when a research team published a paper that opened with the line, “… information about … great white sharks has been difficult to acquire, not least because of the rarity and huge size of this fish.”

    The authors of that study compared genetic samples taken from dozens of sharks in Australia, New Zealand and South Africa. They found that though the DNA produced and stored in the nuclei of their cells were mostly the same between individuals, the mitochondrial DNA of sharks from South Africa were distinctly different from those in Australia and New Zealand.

    The seemingly obvious explanation was that great whites tend to stick together and rarely make forays into neighboring groups. Over time, unique genetic mutations would have accumulated in each group, which, if it went on long enough, would result in the formation of new species.

    This would explain the observed differences in their mitochondrial DNA but not why the nuclear DNA was virtually identical among all three populations. To account for that, the authors suggested that male sharks traveled vast distances throughout the year, but females either never traveled far, or if they did, they most often came back to the same place during the breeding season, a type of migration pattern called philopatry.

    This idea was based on the fact that nuclear and mitochondrial DNA are not inherited in equal proportion in plants and animals. The DNA inside nuclei is passed down by both parents to their offspring, but only one — most often the female — contributes mitochondria to the next generation. This is a holdover from the days when mitochondria were free-living bacteria, before they were unceremoniously engulfed and repurposed by the ancestor of eukaryotes.  

    This was a good guess and had the added benefit of later turning out to be mostly accurate. Male and female great whites do travel large distances in search of food throughout the year, and females consistently make the return journey before it’s time to mate.

    Thus, the nuclear DNA of great whites should have less variation, because itinerant males go around mixing things up, while the mitochondrial DNA in different populations should be distinct because philopatric females ensure all the unique differences stay in one place. This has remained the favored explanation for the last two decades, one that seemed to fit like a well-worn glove. Except, no one ever got around to actually putting it on to test its size. This is primarily because the data needed to do so was hard to get for the same reasons mentioned in the touchstone study: There aren’t many great white sharks, and when researchers do manage to find one, taking a DNA sample without losing any appendages in the process can be tricky business.

    Shark migration cannot explain nuclear and mitochondrial discordance, so what can?

    Naylor and his colleagues began collecting the necessary data back in 2012. “I wanted to get a white shark nuclear genome established to explore its molecular properties,” he said. “White sharks have some very peculiar attributes, and we had about 40 or 50 samples that I thought we could use to design probes to look at their population structure.”

    Over the next few years, they also sequenced DNA from about 150 white shark mitochondrial genomes, which are smaller and less expensive to assemble than their nuclear counterparts. The samples came from all over the world, including the Atlantic, Pacific and Indian oceans.

    When they compared the two types of DNA, they found the same pattern as the one discovered in 2001. At the population level, white sharks in the North Atlantic rarely mixed with those from the South Atlantic. The same was true of sharks in the Pacific and Indian oceans. At a molecular level, the nuclear DNA among all white sharks remained fairly consistent, while the mitochondrial DNA showed a surprising amount of variation.

    The researchers were aware of the philopatric theory and ran a few tests to see if it held up, first by looking specifically at the nuclear DNA. If the act of returning to the same place to mate really were the cause of the strange mitochondrial patterns, some small signal of that should also show up in the nuclear DNA, of which females contribute half to their offspring.

    “But that wasn’t reflected in the nuclear data at all,” Naylor said.

    Next, they concocted a sophisticated test for the mitochondrial genomes. To do this, they first had to reconstruct the recent evolutionary history of white sharks, which is how they discovered the single southern population they’d been reduced to during the last ice age.

    “They were really few and far between when sea levels were lowest. Then the population increased and moved northward as the ice melted. We suspect they remained in those northern waters because they found a reliable food source,” Naylor said. Specifically, they encountered seals, which are a dietary staple among white sharks and one of the main reasons why they have such a strong fidelity to specific locations.

    “These white sharks come along, get a nice blubbery sausage. They fatten up, they breed, and then they move off around the ocean.”

    Knowing when the sharks split up was key, as each group would have begun genetically diverging from each other at this time. All the researchers had to do was determine whether the 10,000 years between now and the last ice age would have been enough time for the mitochondrial DNA to have accumulated the number of differences observed in the data if philopatry was the primary culprit.

    They ran a simulation to find the answer, which came back negative. Philopatry is undoubtedly a behavioral pattern among great whites, but it was not responsible for the large mitochondrial schism.

    So Naylor and his colleagues went back to the drawing board to figure out what sort of evolutionary force could account for the differences.

    “I came up with the idea that sex ratios might be different — that just a few females were contributing to the populations from one generation to the next,” Naylor said. This type of reproductive skew can be observed in a variety of organisms, including meerkats, cichlid fish and many types of social insects.

    But yet another test showed that reproductive skew did not apply to white sharks.

    There is a third, albeit less likely, option the team members said they can’t rule out at this stage, namely that natural selection is responsible for the differences. The reason why this is far-fetched has to do with the relative strength of evolutionary forces. Natural selection — the idea that the organisms best suited to leave behind offspring will, in fact, generally be the ones that have the most offspring — is always active, but it has the strongest effect in large populations. Smaller populations, in contrast, are more susceptible to something called genetic drift, in which random traits — even harmful ones — have a much higher chance of being passed down to the next generation.

    Florida panthers, for example, are highly endangered, with only a few hundred individuals left in the wild. Most of them have a kink at the end of their tail, likely inherited from a single ancestor. In a large population, subject primarily to natural selection, this trait would have either remained uncommon or disappeared entirely over time. But in a small population, a single cat with a kinked tail can change the world purely by chance through the auspices of genetic drift.

    By way of comparison, gravity exerts a force at all scales of matter and energy, but it is by far the weakest of the four fundamental physical forces. At the scale of planets and stars, gravity can hold solar systems and galaxies together, but it has very little influence on the shape or interactions of atoms, which are governed by the three stronger but more localized forces, such as electromagnetism.

    According to the study’s results, genetic drift cannot explain the differences between mitochondria in great whites. Because it is a completely random process, it cannot selectively target one type of DNA and spare another. If it were the culprit, similar changes would also be evident in the nuclear DNA.

    This leaves natural selection as the only other possibility, which seems unlikely because of the small population sizes among white sharks. If it is the causative agent, Naylor said, the selective force “would have to be brutally lethal.”

    If you collect enough mass in a concentrated space, say on the order of a black hole, the otherwise benign force of gravity becomes powerful enough to devour light.

    If natural selection is at play in this case, it would manifest itself in a similarly powerful way. Any deviation from the mitochondrial DNA sequence most common in a given population would likely be fatal, thus ensuring it was not passed on to the next generation.

    But this is far from certain, and Naylor has his doubts about the validity of such a conclusion. For now, scientists are left with an open-ended question that can only be resolved with further study.

    Reference: Laso-Jadart R, Corrigan SL, Yang L, et al. A genomic test of sex-biased dispersal in white sharks. Proc Natl Acad Sci USA. 2025;122(32):e2507931122. doi: 10.1073/pnas.2507931122

    This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

    Continue Reading

  • Evotec SE to announce first half-year results 2025 on 13 August 2025

    About Evotec SE
    Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.

    Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

    With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.

    Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.

    With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.

    Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

    Forward-looking statements
    This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.


    Continue Reading

  • DG ISPR rubbishes rumours of army chief becoming president – Pakistan

    DG ISPR rubbishes rumours of army chief becoming president – Pakistan

    Military spokesperson Lt Gen Ahmed Sharif Chaudhry has rubbished rumours of Chief of Army Staff (COAS) Field Marshal Asim Munir becoming the president.

    His statement follows a similar rebuttal by Interior Minister Mohsin Naqvi early in July, when he clarified that no idea existed “about the president being asked to resign or the COAS aspiring to assume the presidency”.

    Gen Chaudhry, the Inter-Services Public Relations (ISPR) director general, told The Economist that “talk of his boss becoming president is ‘nonsense’”.

    The Economist noted that COAS Munir’s popularity has surged since the May conflict with India. It added that the ruling coalition’s recently acquired two-thirds majority in the parliament needed for a Constitutional Amendment “ignited rumours that the army chief could become president too”.

    The government, as well as the military, have repeatedly warned about “fake news and propaganda” proliferating on social media, with Gen Chaudhry saying that not enough was being done against “digital terrorism” under the laws.

    On July 10, Naqvi asserted that President Asif Ali Zardari “enjoys a strong and respectful relationship with the leadership of the armed forces”.

    He quoted the president as having “clearly” stated: “I know who is spreading these falsehoods, why they are doing so, and who stands to benefit from this propaganda.”

    Naqvi stressed that the “sole focus” of COAS Munir was Pakistan’s strength and stability, and “nothing else”.

    In May, President Zardari and Prime Minister Shehbaz Sharif formally decorated COAS Munir with the rank of field marshal for his “sagacious leadership and exceptional strategy” during the recent conflict with India.

    The rank of field marshal is the highest rank of armies built on the pattern of the British Army. It has only been awarded to one other — Gen Ayub Khan — by the presidential cabinet in 1959. It is a ceremonial five-star rank that usually signifies extraordinary leadership and wartime achievement.

    In a subsequent dinner hosted by the army chief, Field Marshal Munir lauded the political leadership for their “strategic foresight” during Marka-i-Haq against India.

    The next month, Defence Minister Khawaja Asif, who belongs to PM Shehbaz’s PML-N, hailed the “existing hybrid model of governance” in the country. In a separate interview, he also termed it as a “practical necessity” for Pakistan, saying the system was “doing wonders”.

    Continue Reading

  • Tracing ACLY from cardiovascular target to liver therapy lead

    Tracing ACLY from cardiovascular target to liver therapy lead

    Can a cholesterol enzyme help treat an untreatable liver disease? Esperion’s ACLY programme is using multiomic and preclinical data to evaluate its potential in primary sclerosing cholangitis.

    Digital illustration of a liver formed by blue polygonal wireframe, positioned beneath an open capsule releasing glowing particles, symbolizing targeted drug delivery or liver-specific therapy. The futuristic style reflects medical innovation and biotechnology.


    ATP citrate lyase (ACLY) is a central enzyme in metabolism, best known for its role in cholesterol and fatty acid synthesis. A validated target in cardiovascular disease, new research from Esperion Therapeutics suggests that ACLY could also play a role in liver disease – specifically, primary sclerosing cholangitis (PSC).

    PSC is a rare, chronic cholestatic liver disorder with no approved treatments. Its aetiology remains unclear but is characterised by ongoing inflammation and fibrosis of the bile ducts, often progressing to liver failure. With limited therapeutic targets and high unmet need, PSC remains one of the most challenging conditions in hepatology.

    Using large-scale genetic data, multiomic analysis and targeted preclinical studies, the team at Esperion is building a case for ACLY inhibition in PSC. The approach could offer a new angle on a disease that has thus far resisted most conventional drug development strategies.

    At Esperion Therapeutics, the link between ACLY and liver disease did not emerge by chance. It was the result of a deliberate, data-driven investigation that began with established cholesterol biology and led into entirely new therapeutic territory.

    “It’s been like a detective story,” says Stephen Pinkosky, Vice President of Drug Discovery and Early Development at Esperion. As with many such investigations, it began with a familiar target – ACLY – showing unexpected behaviour in a different disease.

    Digital illustration of a human liver with a glowing red center and radiating rings, symbolizing liver inflammation and damage, shown in a futuristic wireframe style.

Digital illustration of a human liver with a glowing red center and radiating rings, symbolizing liver inflammation and damage, shown in a futuristic wireframe style.

    Liver injury and immune activation are key features of primary sclerosing cholangitis (PSC) and central to ACLY’s role in disease progression. Image credit: Vector_Leart / Shutterstock

    From heart disease to liver inflammation

    ACLY sits at the crossroads of sugar and fat metabolism, converting citrate into acetyl-CoA – a critical building block for lipid synthesis. Inhibiting ACLY has been shown to reduce LDL cholesterol (LDL-C) and lower cardiovascular risk. Esperion’s approved therapies are already based on this mechanism.

    Earlier work made clear that ACLY played a key role in cholesterol metabolism in a specific cell type in the liver.

    Yet something new was starting to surface. “Earlier work made clear that ACLY played a key role in cholesterol metabolism in a specific cell type in the liver,” Pinkosky explains. “Emerging evidence was indicating that the role of ACLY might be much broader but knowing where to focus was challenging.”

    Rather than being confined to hepatocytes or lipid levels, dysregulated ACLY activity appeared to contribute to immune dysfunction, inflammation and fibrosis – all central to PSC.

    Follow the data

    How did a programme focused on cardiovascular metabolism come to uncover a potential role for ACLY in a complex liver disease like PSC?

    “Working with our collaborator, we found that ACLY is causally associated with multiple clinical liver outcomes in a very broad population,” says Pinkosky. The insight came through phenome-wide association studies (PheWAS), which combine large genomic datasets with clinical outcomes to identify statistically significant genetic associations.

    We found that ACLY is causally associated with multiple clinical liver outcomes in a very broad population.

    However, associations alone were not sufficient. To justify moving into a new disease area, the biology had to be traced from gene variant to disease process.

    “Mechanistic investigations by our team and others had begun to support a role of ACLY in liver immune cells, inflammatory cells and fibroblasts. But rather than increasing LDL-C, ACLY dysregulation contributes to inflammation, fibrosis and immune dysfunction.”

    Esperion needed more than correlation. They needed a detailed map of how ACLY interacted with liver disease processes.

    Building a liver disease network from scratch

    “No single existing dataset captures the complexity of liver disease well enough, so we built our own multilayer network using several multiomic datasets from patients with a common form of liver disease,” Pinkosky explains.

    By integrating transcriptomic, proteomic and other multiomic data – and applying machine learning and AI – the team developed a systems-level model of liver disease. This approach allowed them not only to identify disrupted pathways, but also to understand how those pathways interact and contribute to disease progression.

    “Creating a rank order of liver diseases in which ACLY could be important, we found that both chronic and immune forms of cholangitis were at the top,” he says.

    PSC stood out immediately – both for its biology and the urgent unmet clinical need.

    Designing drugs for a disease without a known cause

    Esperion then began screening ACLY inhibitors for activity relevant to PSC. However, this was far from a typical hit-to-lead process, as the disease has no clear cause or universal biomarker, so it’s unclear which endpoints to prioritise.

    The cause of PSC is unknown, making it difficult to determine which drug effects to prioritise during discovery and optimisation.

    “The cause of PSC is unknown, making it difficult to determine which drug effects to prioritise during discovery and optimisation,” says Pinkosky.

    Rather than seeking a single causal mechanism, the team concentrated on addressing the downstream biological consequences. “Those datasets helped us to identify novel ACLY pathways that are dysregulated in patients with a common form of liver disease, but also relevant to PSC.”

    Esperion’s compound screens were specifically designed to measure how candidates affected immune, inflammatory and fibrotic signalling. “We then built tests into our screening cascade that allowed us to design and validate compounds that appeared to improve the dysregulation in those pathways,” he says.

    The models that matter

    Even with compelling computational data and validated targets, demonstration of preclinical efficacy in biological systems was still required.

    “Even though we had significant evidence from human genetics and multiomics that ACLY was a good target for liver disease, we still need to conduct interventional preclinical studies to test whether our inhibitors actually do what we designed them to do.”

    Even though we had significant evidence from human genetics and multiomics that ACLY was a good target for liver disease, we still need to conduct interventional preclinical studies to test whether our inhibitors actually do what we designed them to do.

    “No single model captures all of the complicated processes that lead to liver disease in humans,” Pinkosky says. “So, we needed to use multiple models and understand the strengths and weaknesses of each when testing our potential drug candidates.”

    In vivo studies showed reductions in inflammation, fibrosis and liver injury – key hallmarks of PSC. Equally encouraging were results from 3D human liver microtissues, which more closely reflect human disease.

    “The human microtissue approach gave us confidence that these effects will be relevant in humans. This ability to address the injury, as well as the resulting inflammation and fibrosis, makes us optimistic about our findings,” Pinkosky asserts.

    Not just a target

    For Esperion, the ACLY programme is not only about targeting a single enzyme. It is about creating a discovery framework that integrates population-scale genetic data, computational modelling and translational biology to reduce the risks of early-stage development.

    “What excites me about PheWAS and multiomics is that they can help to bridge the gap between preclinical models and patients,” reveals Pinkosky.

    One key resource was the UK BioBank – a dataset of genomic and phenotypic information from over 500,000 individuals. “Applying PheWAS to that data revealed consistent associations of genetically predicted ACLY inhibition with significant reductions in the risk of liver disorders.

    “Multiomics analyses took us even further, helping to validate existing disease pathways and identify new ones rather than hoping that preclinical models alone would get it right.”

    “A unique game-changer”

    If ACLY inhibition can successfully reduce inflammation, fibrosis and immune dysregulation in PSC, it may offer a fundamentally new approach to treating the disease.

    “Complex diseases such as PSC almost invariably require multifaceted treatments, which is what we believe sets us apart,” says Pinkosky.

    “By targeting ACLY – one pathway – we hope to achieve multiple cell-specific effects. Potentially, this will enable our drug candidate to address both the injury component of PSC and the resulting immune, inflammatory and fibrotic responses.

    “In plain English, our goal is to stop the damage and to keep it from recurring: a unique game-changer.”

    What comes next

    Before clinical trials can begin, Esperion will complete a series of regulated preclinical safety studies and continue refining its understanding of ACLY’s role in PSC. The team is also focused on developing robust biomarkers to measure ACLY inhibition and its downstream effects in future trials.

    “Our Esperion team is also focused on discovering and developing biomarkers, which will help us understand how well the drug is inhibiting ACLY in future clinical studies and whether it is having the expected downstream effects on PSC.

    “There is much work left to be done,” says Pinkosky, “but we’re quite optimistic about where this effort will lead.”

    Stephen-PinkoskyStephen-PinkoskyMeet Stephen Pinkosky

    Stephen Pinkosky, PhD, has served as Vice President of Drug Discovery and Development at Esperion since August 2024. Prior to assuming his current role, Dr Pinkosky held positions of increasing responsibility at the company, which he joined in 2008. Before joining Esperion, he worked as a Scientist in the Research and Development Department at Aastrom Biosciences, Inc., a Scientist in Vascular Biology at Esperion Therapeutics, a Pfizer Inc. company, and as an Associate Scientist in Inflammation Pharmacology at Pfizer Global Research and Development.

    With more than 20 years’ experience in the pharmaceutical industry, Dr Pinkosky specialises in the strategic leadership of innovative drug discovery programmes through IND. He has a proven track record of successfully managing cross-functional teams, optimising research pipelines, and fostering collaboration between R&D, clinical, and commercial operations to deliver high-quality therapeutic solutions.

    Dr Pinkosky holds a PhD in Nutrition and Metabolism from the School of Medicine at McMaster University in Canada and a Master of Science degree in Molecular, Cellular and Developmental Biology from the University of Michigan.

     

    Continue Reading

  • Scientists just found a massive earthquake threat hiding beneath Yukon

    Scientists just found a massive earthquake threat hiding beneath Yukon

    New research led by the University of Victoria (UVic) has illuminated a significant and previously unrecognized source of seismic hazard for the Yukon Territory of northwestern Canada.

    The Tintina fault is a major geologic fault approximately 1,000 km long that trends northwestward across the entire territory. It has slipped laterally a total of 450 km in its lifetime but was previously believed to have been inactive for at least 40 million years. However, using new high-resolution topographic data collected from satellites, airplanes and drones, researchers have identified a 130-km-long segment of the fault near Dawson City where there is evidence of numerous large earthquakes in the much more recent geologic past (the Quaternary Period, 2.6 million years to present), indicating possible future earthquakes.

    “Over the past couple of decades there have been a few small earthquakes of magnitude 3 to 4 detected along the Tintina fault, but nothing to suggest it is capable of large ruptures,” says Theron Finley, recent UVic PhD graduate and lead author of the recent article in Geophysical Research Letters. “The expanding availability of high-resolution data prompted us to re-examine the fault, looking for evidence of prehistoric earthquakes in the landscape.”

    Currently, the understanding of earthquake rates and seismic hazard in much of Canada is based on a catalogue of earthquakes from oral Indigenous accounts, written historical records and modern seismic monitoring networks. Collectively, these records only cover the last couple hundred years. However, for many active faults, thousands of years can elapse between large ruptures.

    When earthquakes are large and/or shallow, they often rupture the Earth’s surface and produce a linear feature in the landscape known as a fault scarp. These features, which can persist in the landscape for thousands of years, are typically tens to hundreds of kilometers long, but only a few metres wide and tall. They are difficult to detect in heavily forested regions like Canada, and require extremely high-resolution topographic data to identify.

    The team, consisting of researchers from UVic, the Geological Survey of Canada and University of Alberta, used high resolution topographic data from the ArcticDEM dataset from satellite images, as well as from light detection and ranging (lidar) surveys conducted with airplanes and drones. They identified a series of fault scarps passing within 20 km of Dawson City.

    Crucially, they observed that glacial landforms 2.6 million years in age are laterally offset across the fault scarp by 1000 m. Others, 132,000 years old, are laterally offset by 75 m. These findings confirm that the fault has slipped in multiple earthquakes throughout the Quaternary period, likely slipping several meters in each event. What’s more, landforms known to be 12,000 years old are not offset by the fault, indicating no large ruptures have occurred since that time. The fault continues to accumulate strain at an average rate of 0.2 to 0.8 millimetres per year, and therefore poses a future earthquake threat.

    “We determined that future earthquakes on the Tintina fault could exceed magnitude 7.5,” says Finley. “Based on the data, we think that the fault may be at a relatively late stage of a seismic cycle, having accrued a slip deficit, or build-up of strain, of six meters in the last 12,000 years. If this were to be released, it would cause a significant earthquake.”

    An earthquake of magnitude 7.5 or greater would cause severe shaking in Dawson City and could pose a threat to nearby highways and mining infrastructure. Compounding the hazard from seismic shaking, the region is prone to landslides, which could be seismically triggered. The Moosehide landslide immediately north of Dawson City and the newly discovered Sunnydale landslide directly across the Yukon River both show ongoing signs of instability.

    Canada’s National Seismic Hazard Model (NSHM) includes the potential for large earthquakes in central Yukon Territory, but the Tintina fault is not currently recognized as a discrete seismogenic fault source. The recent findings by this team will ultimately be integrated into the NSHM, which informs seismic building codes and other engineering standards that protect human lives and critical infrastructure. The findings will also be shared with local governments and emergency managers to improve earthquake readiness in their communities.

    This research occurred on the territory of the Tr’ondëk Hwëch’in and Na-Cho Nyäk Dun First Nations

    Continue Reading

  • Arasan Announces the industries first MIPI SWI3S Manager IP and Peripheral Controller IP

    Arasan Chip Systems, a leading provider of semiconductor IP for mobile and automobile SoCs, today announced the industry’s first  SWI3S Manager IP and Peripheral IP Cores

    SAN JOSE, Calif., Aug. 6, 2025 /PRNewswire/ — Arasan Chip Systems, a leading provider of semiconductor IP for mobile and automobile SoCs, today announced the immediate availability of the industry’s first MIPI SWI3S Manager IP and SWI3S Peripheral IP Cores. The SWI3S IP gate count is kept extremely low, targeting applications like the Microphones while also ensuring low latency.

    Arasan’s SWI3S IP joins Arasan’s extensive MIPI IP portfolio which includes its Soundwire IP, CSI, DSI, CDPHY and DPHY IP.  Arasan is the industry’s first provider of IP for the MIPI standards and has been an executive member of the MIPI Association since 2005.

    The MIPI SWI3S IP is used to connect digital audio components such as Digital Microphone, Audio Codecs, Amplifiers, Headset and docking audio, DSPs etc. on mobile devices.

    Features of SoundWire I3S IP:

    Fewer Wires → Simplifies PCB layout 

    Lower Power → Ideal for battery-powered devices 

    High Bandwidth → Handles multi-channel high-res audio 

    Integrated Control + Audio → No separate control bus needed

    Arasan’s SWI3S Manager IP and SWI3S Peripheral Controller Core IP implement the link protocol to communicate in half-duplex fashion to transfer the Audio streams and the Control information together. One or more SWI3S Peripheral IP can be connected specific to the application.

    “Arasan is proud to announce the industry’s first SWI3S IP. Arasan’s offers a focussed portfolio of IP products and services targeting the Mobile SoC market and it is imperative to our business that we are the first while also ensuring compliance with the standards. We are proud to be first again with our SWI3S IP.” said Ron Mabry, VP of Sales at Arasan.

    For more information, visit: https://www.arasan.com/product/swi3s-manager-core-ip/

    Availability

    The Arasan SoundWire I3S IP is available immediately for ASIC and FPGA applications. Please contact [email protected] for product enquiries.

    About Arasan:
    Arasan Chip Systems is a leading provider of IP for mobile storage and mobile connectivity interfaces, with over a billion chips shipped with our IP. Our high-quality, silicon-proven Total IP Solutions encompass digital IP, Analog Mixed Signal PHY IP, Verification IP, HDK, and Software. With a strong focus on mobile SoCs, we have been at the forefront of the Mobile evolution since the mid-90s, supporting various mobile devices, including smartphones, automobiles, drones, and IoT devices, with our standards-based IP.

    Photo – https://mma.prnewswire.com/media/2743771/SWI3S_Block_Diagram.jpg
    Logo – https://mma.prnewswire.com/media/2724571/Arasan_Chip_Systems_Inc_Logo.jpg

    Continue Reading